Quick Answer
HAEMONETICS CORP reported R&D Expense of $62.72 million for fiscal year 2025.
HAEMONETICS CORP R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $62.72M | +15.2% |
| 2024 | $54.44M | +8.6% |
| 2023 | $50.13M | +7.1% |
| 2022 | $46.80M | +42.4% |
| 2021 | $32.86M | +6.4% |
| 2020 | $30.88M | -13.5% |
| 2019 | $35.71M | -9.0% |
| 2018 | $39.23M | +4.5% |
| 2017 | $37.56M | -16.5% |
| 2016 | $44.97M | -17.0% |
| 2015 | $54.19M | -0.0% |
| 2014 | $54.20M | +22.1% |
| 2013 | $44.39M | +20.6% |
| 2012 | $36.80M | +12.7% |
| 2011 | $32.66M | +23.8% |
| 2010 | $26.38M | +10.5% |
| 2009 | $23.86M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $14.19M | -10.4% | -4.6% |
| September 30, 2025 | $14.87M | +5.2% | -8.5% |
| June 30, 2025 | $16.26M | +12.5% | +2.7% |
| December 31, 2024 | $15.83M | +19.3% | +12.0% |
| September 30, 2024 | $14.14M | +11.6% | -2.1% |
| June 30, 2024 | $14.45M | +14.2% | +8.9% |
| December 31, 2023 | $13.27M | +4.5% | +4.7% |
| September 30, 2023 | $12.66M | +16.2% | +0.1% |
- HAEMONETICS CORP showed an increase of +15.2% in R&D Expense compared to the prior fiscal year.
- Over the 2009–2025 period, HAEMONETICS CORP’s r&d expense has grown by 162.9% (from $23.86 million to $62.72 million).
- The most recent figure is from HAEMONETICS CORP’s fiscal year 2024 report (Form 10-K), filed with the SEC on May 21, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: